Skip to main content

Table 2 The characteristics of patients with ROS1 rearrangement

From: Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement

Cases No. Smokinga Staging/Gradingb IHC resultc H-score FISH result Direct sequencing Histopathology predominant pattern Staining Pattern Another gene aberranced
1 N II B/
Score 5/Grade 2
3+/90 % 260 Fusion positive SLC34A2-E4; ROS1-E32/SLC34A2-E4; ROS1-E34 Acinar Cytoplasmic; membrane ALK\EGFR\KRAS(−)
2 N I A/Score 3/Grade 2/ 2+/65 % 150 Fusion positive CD74-E6; ROS1-E34 Acinar Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
3 P IV/−/− 2+/70 % 160 Fusion positive CD74-E6; ROS1-E34 Invasive mucinous adenocarcinoma Mucinous staining ALK\EGFR\KRAS(−)
4 N I A/Score 5/Grade 2 2+/90 % 200 Fusion positive TPM3-E8; ROS1-E35 Papillary and acinar Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
5 N I A/Socre 5/Grade 3 2+/90 % 200 Fusion positive SLC34A2-E14del; ROS1-E32/SLC34A2-E14del; ROS1-E34 Papillary and micropapillary Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
6 N IV/ Socre4/Grade 2 3+/85 % 250 Fusion positive CD74-E6; ROS-E34 Acinar Cytoplasmic; granular ALK\EGFR\KRAS(−)
7e N IV/−/− 2+/70 % 160 Fusion positive Invasive adenocarcinoma with acinar pattern Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
8 S I A/Score 5/Grade 3 3+/90 % 250 Fusion positive Papillary and micropapillary Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
9 S I B/Socre 3/Grade 2 2+/80 % 180 Fusion positive Acinar and lepidic Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
10 N I B/Score 3/Grade 1 2+/80 % 180 Fusion positive Lepidic Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
  1. a N, non-smoker; S, smoker; P, previous smoker
  2. bTNM staging, SICA grading and WHO grading
  3. cIHC results were containing intensity and extent scores
  4. dALK rearrangement, EGFR and KRAS mutation have been also investigated at the sme time. The cases harboring ROS1 rearrangement were exclusive to ALK rearrangement, EGFR and KRAS mutation
  5. ecases 7 was biopsy sample